Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129969581> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3129969581 abstract "To determine the incidence of skeletal-related events among multiple myeloma patients who received chemotherapy without a bone-modifying agent (zoledronic acid and denosumab) versus those who received chemotherapy with a bone-modifying agent. The secondary objective was to determine the incidence of skeletal-related events in patients without any prior history of skeletal-related events and who were treated with zoledronic acid every four weeks versus those who received zoledronic acid at an extended interval of every twelve weeks. Additional secondary objectives included the incidence of nephrotoxicity, hypocalcemia and osteonecrosis of the jaw in all patients.This institutional review board-approved, retrospective cohort study included patients 18 to 89 years old with a diagnosis of multiple myeloma, who were being treated with chemotherapy between July 1, 2016 and October 31, 2019. Safety and efficacy were assessed through analysis of pertinent data collected: patient demographics, baseline skeletal-related events, development of new skeletal-related events, number and type of bone-modifying agent doses administered, and drug-related toxicities such as nephrotoxicity, hypocalcemia, and osteonecrosis of the jaw.A total of 73 patients were included. New skeletal-related events occurred in 12 patients (27%) in the chemotherapy without a bone-modifying agent group and in 5 patients (17%) in the chemotherapy with a bone-modifying agent group (OR = 0.56, 95% CI [0.172-1.8]; P = 0.32). The incidence of skeletal-related events was similar among patients receiving zoledronic acid every four weeks versus every twelve weeks in patients without a prior skeletal-related event (N = 0 vs. N = 2 respectively; P = 0.47). There were no statistically significant differences observed in each of the three secondary safety endpoints: incidence of hypocalcemia, nephrotoxicity and osteonecrosis of the jaw.Multiple myeloma patients receiving chemotherapy without a bone-modifying agent had higher rates of skeletal-related events compared to those being treated with chemotherapy and a bonemodifying agent. Our results highlight the benefit of utilizing bonemodifying agents for the prevention of skeletal-related events in all multiple myeloma patients being treated with chemotherapy." @default.
- W3129969581 created "2021-03-01" @default.
- W3129969581 creator A5004396013 @default.
- W3129969581 creator A5024413510 @default.
- W3129969581 creator A5025243512 @default.
- W3129969581 creator A5039462069 @default.
- W3129969581 date "2021-02-16" @default.
- W3129969581 modified "2023-10-17" @default.
- W3129969581 title "Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study" @default.
- W3129969581 cites W1972714302 @default.
- W3129969581 cites W2562306819 @default.
- W3129969581 cites W2782600446 @default.
- W3129969581 cites W2783965560 @default.
- W3129969581 doi "https://doi.org/10.1177/1078155221996039" @default.
- W3129969581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33593137" @default.
- W3129969581 hasPublicationYear "2021" @default.
- W3129969581 type Work @default.
- W3129969581 sameAs 3129969581 @default.
- W3129969581 citedByCount "1" @default.
- W3129969581 crossrefType "journal-article" @default.
- W3129969581 hasAuthorship W3129969581A5004396013 @default.
- W3129969581 hasAuthorship W3129969581A5024413510 @default.
- W3129969581 hasAuthorship W3129969581A5025243512 @default.
- W3129969581 hasAuthorship W3129969581A5039462069 @default.
- W3129969581 hasConcept C120665830 @default.
- W3129969581 hasConcept C121332964 @default.
- W3129969581 hasConcept C126322002 @default.
- W3129969581 hasConcept C141071460 @default.
- W3129969581 hasConcept C167135981 @default.
- W3129969581 hasConcept C2776286101 @default.
- W3129969581 hasConcept C2776326535 @default.
- W3129969581 hasConcept C2776364478 @default.
- W3129969581 hasConcept C2776541429 @default.
- W3129969581 hasConcept C2776694085 @default.
- W3129969581 hasConcept C2777251235 @default.
- W3129969581 hasConcept C2777556957 @default.
- W3129969581 hasConcept C61511704 @default.
- W3129969581 hasConcept C71924100 @default.
- W3129969581 hasConceptScore W3129969581C120665830 @default.
- W3129969581 hasConceptScore W3129969581C121332964 @default.
- W3129969581 hasConceptScore W3129969581C126322002 @default.
- W3129969581 hasConceptScore W3129969581C141071460 @default.
- W3129969581 hasConceptScore W3129969581C167135981 @default.
- W3129969581 hasConceptScore W3129969581C2776286101 @default.
- W3129969581 hasConceptScore W3129969581C2776326535 @default.
- W3129969581 hasConceptScore W3129969581C2776364478 @default.
- W3129969581 hasConceptScore W3129969581C2776541429 @default.
- W3129969581 hasConceptScore W3129969581C2776694085 @default.
- W3129969581 hasConceptScore W3129969581C2777251235 @default.
- W3129969581 hasConceptScore W3129969581C2777556957 @default.
- W3129969581 hasConceptScore W3129969581C61511704 @default.
- W3129969581 hasConceptScore W3129969581C71924100 @default.
- W3129969581 hasLocation W31299695811 @default.
- W3129969581 hasLocation W31299695812 @default.
- W3129969581 hasOpenAccess W3129969581 @default.
- W3129969581 hasPrimaryLocation W31299695811 @default.
- W3129969581 hasRelatedWork W10198250 @default.
- W3129969581 hasRelatedWork W12087825 @default.
- W3129969581 hasRelatedWork W15495912 @default.
- W3129969581 hasRelatedWork W16019997 @default.
- W3129969581 hasRelatedWork W17521974 @default.
- W3129969581 hasRelatedWork W19571804 @default.
- W3129969581 hasRelatedWork W20915983 @default.
- W3129969581 hasRelatedWork W278444 @default.
- W3129969581 hasRelatedWork W3998621 @default.
- W3129969581 hasRelatedWork W4703887 @default.
- W3129969581 isParatext "false" @default.
- W3129969581 isRetracted "false" @default.
- W3129969581 magId "3129969581" @default.
- W3129969581 workType "article" @default.